Growth Metrics

Solid Biosciences (SLDB) Capital Expenditures (2017 - 2024)

Historic Capital Expenditures for Solid Biosciences (SLDB) over the last 8 years, with Q4 2024 value amounting to $204000.0.

  • Solid Biosciences' Capital Expenditures rose 12666.67% to $204000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $654000.0, marking a year-over-year decrease of 5683.17%. This contributed to the annual value of $654000.0 for FY2024, which is 5683.17% down from last year.
  • As of Q4 2024, Solid Biosciences' Capital Expenditures stood at $204000.0, which was up 12666.67% from $15000.0 recorded in Q3 2024.
  • In the past 5 years, Solid Biosciences' Capital Expenditures registered a high of $1.1 million during Q2 2022, and its lowest value of $15000.0 during Q3 2024.
  • In the last 5 years, Solid Biosciences' Capital Expenditures had a median value of $275000.0 in 2022 and averaged $368200.0.
  • As far as peak fluctuations go, Solid Biosciences' Capital Expenditures soared by 100000.0% in 2021, and later plummeted by 9608.36% in 2024.
  • Over the past 5 years, Solid Biosciences' Capital Expenditures (Quarter) stood at $60000.0 in 2020, then skyrocketed by 1000.0% to $660000.0 in 2021, then rose by 29.7% to $856000.0 in 2022, then tumbled by 89.49% to $90000.0 in 2023, then surged by 126.67% to $204000.0 in 2024.
  • Its Capital Expenditures was $204000.0 in Q4 2024, compared to $15000.0 in Q3 2024 and $286000.0 in Q2 2024.